Coherus Oncology, Inc. (CHRS): Total Liabilities

Annual figures by period end, from SEC filings.

$197.33M
As of 2025-12-31
$130.34M
As of 2026-06-30
-31.7%
3-year compound annual growth
-18.8%
5-year compound annual growth
-1.1%
10-year compound annual growth
$823.03M2013-12-31: $89.83M2014-12-31: $120.46M2015-12-31: $219.31M2016-12-31: $159.13M2017-12-31: $132.08M2018-12-31: $138.06M2019-12-31: $303.71M2020-12-31: $560.67M2021-12-31: $581.61M2022-12-31: $618.26M2023-12-31: $823.03M2024-12-31: $580.52M2025-12-31: $197.33M$197.33M
2013-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$197.33M-66.0%2026-03-09, Balance as of period end
2024-12-31$580.52M-29.5%2026-03-09, Balance as of period end
2023-12-31$823.03M+33.1%2025-03-17, Balance as of period end
2022-12-31$618.26M+6.3%2024-03-15, Balance as of period end
2021-12-31$581.61M+3.7%2023-03-06, Balance as of period end
2020-12-31$560.67M+84.6%2022-02-23, Balance as of period end
2019-12-31$303.71M+120.0%2021-02-25, Balance as of period end
2018-12-31$138.06M+4.5%2020-02-27, Balance as of period end
2017-12-31$132.08M-17.0%2019-02-28, Balance as of period end
2016-12-31$159.13M-27.4%2018-03-08, Balance as of period end
2015-12-31$219.31M+82.1%2017-03-14, Balance as of period end
2014-12-31$120.46M+34.1%2016-02-29, Balance as of period end
2013-12-31$89.83Mn/a2015-03-23, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Coherus Oncology, Inc. (CHRS)2025-12-31$197.33M-66.0%
Tectonic Therapeutic, Inc. (TECX)2025-12-31$9.71M-20.0%
Voyager Therapeutics, Inc. (VYGR)2025-12-31$56.20M-39.8%
Lexeo Therapeutics, Inc. (LXEO)2025-12-31$22.02M-26.8%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$234.11M-3.7%
MeiraGTx Holdings plc (MGTX)2025-12-31$250.22M+23.9%
Invivyd, Inc. (IVVD)2025-12-31$35.34M-43.0%
DBV Technologies S.A. (DBVT)2025-12-31$64.95M+69.7%
Solid Biosciences Inc. (SLDB)2025-12-31$52.53M+2.2%

Compare CHRS, TECX, VYGR, LXEO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗